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MMRpredict) and fair for MSH6 mutation carriers (0.69 for 
PREMM5 and 0.66 for MMRpredict). MMRpredict per-
formed fair for PMS2 mutation carriers (AUC 0.72), while 
PREMM5 failed to discriminate PMS2 mutation carriers 
from non-mutation carriers (AUC 0.51). The only statisti-
cally significant difference between PMS2 mutation carriers 
and non-mutation carriers was proximal location of colo-
rectal cancer (77 vs. 28%, p < 0.001). Adding location of 
colorectal cancer to PREMM5 considerably improved the 
models performance for PMS2 mutation carriers (AUC 0.77) 
and overall (AUC 0.81 vs. 0.72). We validated these results 
in an external cohort of 376 colorectal cancer patients, 
including 158 LS patients. MMRpredict and PREMM5 
cannot adequately identify PMS2 mutation carriers. Add-
ing location of colorectal cancer to PREMM5 may improve 
the performance of this model, which should be validated 
in larger cohorts.
Keywords Lynch syndrome · Prediction models · 
Colorectal cancer · Hereditary cancer
Introduction
Lynch syndrome (LS) is a hereditary predisposition to colo-
rectal cancer, endometrial cancer and other extra-colonic 
cancers at a young age [1, 2]. Morbidity and mortality of 
LS carriers can be significantly reduced by surveillance pro-
grams [3–5]. Therefore identifying LS carriers is of great 
importance.
LS is caused by a germline mutation in one of the 
mismatch repair (MMR) genes MLH1, MSH2, MSH6 or 
PMS2, or in the 3′ end of the EPCAM gene and consequent 
hypermethylation of the MSH2 promoter region [6–10]. 
As a result, tumours in LS patients are characterized by 
Abstract Until recently, no prediction models for Lynch 
syndrome (LS) had been validated for PMS2 mutation car-
riers. We aimed to evaluate MMRpredict and PREMM5 in 
a clinical cohort and for PMS2 mutation carriers specifi-
cally. In a retrospective, clinic-based cohort we calculated 
predictions for LS according to MMRpredict and PREMM5. 
The area under the operator receiving characteristic curve 
(AUC) was compared between MMRpredict and PREMM5 
for LS patients in general and for different LS genes specifi-
cally. Of 734 index patients, 83 (11%) were diagnosed with 
LS; 23 MLH1, 17 MSH2, 31 MSH6 and 12 PMS2 mutation 
carriers. Both prediction models performed well for MLH1 
and MSH2 (AUC 0.80 and 0.83 for PREMM5 and 0.79 for 
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microsatellite instability (MSI) and by loss of MMR pro-
tein expression in immunohistochemistry (IHC) [11–13]. 
Analysis of MSI and IHC, combined with MLH1 promoter 
methylation analysis to exclude sporadic MMR deficient 
tumours, are used to identify patients with tumours likely 
caused by LS [13]. A definite diagnosis of LS is made when 
a pathogenic germline mutation is found.
The revised Bethesda guidelines were based on a set of 
diagnostic criteria to select patients eligible for LS screen-
ing in tumour tissue. However, due to limited sensitivity, 
many LS patients will likely be missed by these guidelines 
[14–17]. Several prediction models, such as MMRpro, 
MMRpredict and PREMM5 have also been developed to 
calculate an individual’s probability of carrying a germline 
MMR mutation [18–20]. These models could aid in the 
selection of patients at high risk of having LS, for tumour 
analysis or direct germline mutation analysis. MMRpro is 
less useful in clinical practice since detailed information of 
all relatives is needed as input for the model [19]. However, 
MMRpredict and  PREMM1,2,6 (a previous version of the 
newly developed  PREMM5 model) both performed well in 
previous evaluations [21–27]. An advantage of PREMM5 
is that it can also be used for individuals with extracolonic 
malignancies and healthy individuals, as opposed to MMR-
predict, which can only be used for CRC patients. Until 
recently, all prediction models for LS were developed with 
cohorts of patients carrying a MLH1, MSH2, or MSH6 
mutation. The recently published PREMM5 model is the 
only model that included PMS2 mutation carriers in its 
development.
In this study we aimed to evaluate MMRpredict and 
PREMM5 in a clinical cohort and for PMS2 mutation carri-
ers specifically. Additionally, we aimed to identify clinical 
features useful for distinguishing PMS2 mutation carriers 
from non-mutation carriers.
Methods
In a retrospective, clinic-based cohort we assessed the 
performance of MMRpredict and PREMM5 in predicting 
LS mutations in general and for MLH1, MSH2, MSH6 and 
PMS2 mutations specifically. Additionally, we performed 
a univariate analysis to identify variables that can distin-
guish PMS2 mutation carriers from patients with no MMR 
mutation.
Study population
We collected data for all families that were referred for 
genetic counselling at Erasmus MC, Rotterdam, The Nether-
lands, and in which colorectal cancer was analysed for MSI 
and/or IHC between 2000 and 2010. Exclusion criteria were: 
failed or inconclusive analysis for MSI and IHC, a patho-
genic mutation in APC or MUTYH, a variant of unknown 
clinical significance in one of the MMR genes or APC, and 
MSI or IHC suspect for LS while no MMR mutation was 
detected. To increase the number of LS families, 35 LS 
families outside our cohort, diagnosed after 2010, were also 
included in the analysis.
Analysis of MSI and IHC
MSI analysis was carried out with five markers for MSI as 
described previously; up to 2007 the Bethesda panel [28] 
was used and from 2007 onwards our center performs Pro-
mega pentaplex MSI analysis [29]. IHC for MLH1, MSH2, 
MSH6 and PMS2 protein was performed as described previ-
ously [13]. Tumours without MSI or only a low degree of 
MSI and with all MMR proteins present, were considered 
MMR proficient. Tumours showing a high degree of MSI 
and/or absence of one or more MMR proteins, were consid-
ered MMR deficient. MLH1 hypermethylation analysis was 
performed to distinguish between sporadic MMR deficient 
tumours and MMR deficient tumours suspect for LS.
Germline mutation analysis
Patients with MMR deficient tumours suspect for LS under-
went germline mutation analysis of the gene indicated by 
IHC. Germline mutation analysis of MLH1, MSH2 and 
MSH6 was performed by sequencing and multiplex ligation 
dependent probe amplification analyses. PMS2 mutation 
analysis was performed as described elsewhere [30].
Family classification
Tumour characteristics, age at diagnosis, results of molecular 
diagnostics and germline mutation analysis, and a detailed 
family history were collected from medical records. In every 
family the patient in whom MSI and/or IHC was analysed, 
was labelled the index patient. If more than one family mem-
ber was screened for LS, the youngest CRC patient analysed 
was considered the index patient. Index patients with MMR 
proficient tumours or sporadic MMR deficient tumours, were 
labelled non-mutation carriers. Families identified with a 
pathogenic MMR mutation were labelled LS families.
Prediction models
For each index patient the probability of carrying a LS muta-
tion according to MMRpredict and PREMM5 was calculated 
as previously described [18, 20].
For PREMM5, the equation was slightly different from 
the published equation, based on personal communications 
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with F. Kastrinos. See Supplemental Material (Appen-
dix 1) for the corrected PREMM5 equation.
Statistical analysis
Data were analyzed using SPSS statistical software version 
21.0. Differences between mutation carriers and non-muta-
tion carriers were compared using the Chi square test or 
Fishers’ exact test for frequencies, and by using the Mann 
Whitney U test for continuous data. These analysis were 
also performed to compare PMS2 mutation carriers with 
non-mutation carriers. P values < 0.01 were considered 
statistically significant.
Receiver operating characteristic curves were created 
for MMRpredict and PREMM5 by plotting the true posi-
tive rate (sensitivity) against the false positive rate (1- 
specificity). Performance of MMRpredict and PREMM5 
was evaluated by the area under the receiver operating 
characteristic curve (AUC). We compared the AUC of 
PREMM5 and MMRpredict for LS patients in general 
and for the different MMR genes specifically. Sensitiv-
ity and specificity were calculated for cut-offs previously 
indicated by the developers of the models (5, 10, 20 and 
40%). These values were compared with the sensitivity 
and specificity of the revised Bethesda guidelines.
Model updating
Location of CRC is included in MMRpredict, but not in 
the PREMM5 model. To update the PREMM5 model, we 
used a previously proposed framework to update multi-
nomial logistic regression models [31]. We extended the 
PREMM5 model using recalibration and extension. The 
PREMM5 model contains four linear predictors, each con-
tributing weights to the probability of carrying a muta-
tion in MLH1, MSH2 (or TACSTD1), MSH6 and PMS2. 
The coefficients of the linear predictors were constrained 
such that the linear predictor only contributed to the cal-
culation of the corresponding mutation. Since the origi-
nal PREMM5 model was developed on a population with 
no MSH6 mutation carriers with two or more CRCs, we 
developed two adaptations of the PREMM5 model. First 
we recalibrated the PREMM5 model and re-estimated the 
coefficient of the predictor ‘Two or more CRCs’ in the 
linear predictor for MSH6. In the second adaptation we 
also added side of CRC as an additional predictor to the 
original PREMM5 model. Discriminative ability of the 
prediction models was quantified using the AUC. Calcu-
lations were done using R software (version 3.3.0), with 
estimation of the coefficients in the updated PREMM5 
model using the VGAM package.
Validation of the extended PREMM5 model
For external validation of the extended PREMM5 model, 
we used a cohort of 376 CRC patients. Of these patients, 
218 were patients with MMR proficient CRC, that where 
analysed in the Erasmus Medical Center Rotterdam outside 
the dates of our initial cohort. LS patients (n = 158) in our 
validation cohort were CRC patients from Leiden University 
Medical Center in whom an MMR mutation was found and 
with known location of CRC. For all patients of the vali-
dation cohort we calculated the probability of carrying an 
MMR mutation according to the original PREMM5 model 
and the extended model. The performance of both models 
were evaluated by comparing the AUC.
Results
A total of 734 index patients were included in the study; 
346 (47%) were male and mean age at time of diagnosis was 
53 years (± 13 years). Overall, 569 (78%) patients fulfilled 
the revised Bethesda guidelines. Of the 734 index patients, 
83 (11%) were diagnosed with a LS mutation; 23 MLH1, 17 
MSH2, 31 MSH6 and 12 PMS2 mutation carriers.
Patient characteristics
Patient characteristics for mutation-positive and mutation-
negative patients are shown in Table 1. Significantly more 
mutation carriers developed multiple CRCs (21 vs. 10%, 
p = 0.005) and multiple LS-associated cancers in general (13 
vs. 4%, p = 0.002) than non-mutation-carriers. CRC patients 
carrying an MMR mutation had a younger age of onset (49 
vs. 53 years, p = 0.002) and more often had proximal CRCs 
(64 vs. 28%, p < 0.001) than non-mutation carriers. Among 
women, the frequency of EC was higher for mutation carri-
ers than for non-mutation carriers (41 vs. 3%, p < 0.001). In 
the mutation positive group, first and second degree relatives 
developed CRC at a younger age than in the mutation nega-
tive group (50 vs. 64 years, p < 0.001 and 47 vs. 62 years, 
p = 0.008). First degree relatives of mutation carriers had 
higher rates of EC than relatives of non-mutation carriers 
(19 vs. 5%, p < 0.001).
Discriminative ability of prediction models
Overall, PREMM5 predicted higher probabilities of car-
rying a LS mutation than MMRpredict (median score 
0.06 vs. 0.03, Supplemental Table 1). For mutation car-
riers, risk scores varied from 0.02 to 0.99 for PREMM5 
and from 0.002 to 0.99 for MMRpredict. Both prediction 
models could fairly discriminate between index patients 
with and without an MMR mutation.(Fig. 1) PREMM5 
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and MMRpredict had similar overall performance (AUC 
0.72 [95% CI 0.66–0.79] vs. 0.73 [95% CI 0.66–0.79]). For 
MLH1 and MSH2 mutation carriers, both prediction models 
performed well, with AUC of 0.80 [95% CI 0.71–0.89] and 
0.83 [95% CI 0.73–0.94] for PREMM5 and AUC of 0.79 
[95% CI 0.69–0.89 and 0.67–0.91] for MMRpredict. Both 
models had a fair discriminative power for MSH6 mutation 
carriers (AUC of 0.69 [95% CI 0.58–0.80] for PREMM5 and 
AUC of 0.66 [95% CI 0.56–0.76] for MMRpredict). MMR-
predict still had fair performance for PMS2 mutation carriers 
(AUC of 0.72 [95% CI 0.57–0.87]), while PREMM5 failed 
to discriminate PMS2 mutation carriers from non-mutation 
carriers at all with an AUC of 0.51 [95% CI 0.35–0.66].
Sensitivity and specificity
Using a cut-off of 5% for both prediction models, PREMM5 
had a higher sensitivity than MMRpredict (78 vs. 70%). This 
higher sensitivity came at the expense of a lower specificity 
(46 vs. 67%). For PREMM5, using a cut-off of 5%, resulted 
in a sensitivity for MLH1 and MSH2 mutations of 88 and 
91%, while the sensitivity for MSH6 mutation carriers was 
74% and the sensitivity for PMS2 mutation carriers was only 
50%. For MMRpredict, at a 5% cut-off sensitivity for MLH1 
and MSH2 mutation carriers were 74 and 77%, while sensi-
tivity for PMS2 as well as MSH6 mutation carriers were 65 
and 67%. For both models, using a cut-off of ≥ 20% failed 
to identify over 50% of the mutation carriers.
Sensitivity of the revised Bethesda guidelines decreased 
from 96% for MLH1 mutation carriers to 83% for PMS2 
mutation carriers (Supplemental Table  2). Overall, the 
revised Bethesda guidelines had a sensitivity of 90% with 
a specificity of 24%. In order to reach the same sensitivity, 
PREMM5 and MMRpredict had a similar specificity (25%).
PMS2 mutation carriers versus non‑mutation carriers
Mutation carriers differed significantly from non-mutation 
carriers in many ways (Table 1). In contrast, there were 
almost no significant differences between PMS2 mutation 
carriers and non-mutation carriers. Only one significant dif-
ference remained; PMS2 mutation carriers more often had 
proximal CRC than patients without an MMR mutation (83 
vs. 28%, p < 0.001) (Table 2).
Table 1  Index characteristics 
and family history by mutation 
status (n = 734)
Mutation negative, % (n) Mutation positive, % (n) P value
n 651 83
Revised Bethesda guidelines 76% (494) 90% (75) 0.003
Index characteristics
 Male gender 47% (305) 49% (41) 0.66
  CRC
   Age CRC (median, IQR) 53 years [45–62] 49 years [39–59] 0.002
   Proximal CRC 28% (185) 64% (53) < 0.001
   ≥ 2 CRCs 10% (66) 21% (17) 0.005
  Endometrial cancer 3% (11) 41% (17) < 0.001
   Age EC (median, IQR) 55 years [50–75] 54 years [49–57] 0.18
 Multiple LS cancers 4% (27) 13% (11) 0.002
First degree relatives
 CRC 55% (358) 51% (42) 0.45
  ≥ 2 FDRs with CRC 16% (107) 17% (14) 0.92
  Age CRC (median, IQR) 64 years [55–71] 50 years [43–57] < 0.001
 Endometrial cancer 5% (35) 19% (16) < 0.001
  ≥ 2 FDRs with EC 0.6% (4) 2% (2) 0.14
  Age EC (median, IQR) 55 years [50–64] 50 years [45–57] 0.25
 Other LS cancers 22% (142) 19% (16) 0.60
Second degree relatives
 CRC 33% (212) 35% (29) 0.66
  ≥ 2 SDRs with CRC 12% (81) 12% (10) 0.92
  Age CRC (median, IQR) 62 years [50–74] 47 years [38–64] 0.008
 Endometrial cancer 3% (22) 7% (6) 0.12
  ≥ 2 SDRs with EC 0.3% (2) 2% (2) 0.07
  Age EC (median, IQR) 70 years [50–76] 49 years [44–51] 0.13
 Other LS cancers 16% (104) 18% (15) 0.63
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Fig. 1  Performance of PREMM5 and MMRpredict in a clinical setting for all mutation carriers and for individual MMR mutations
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Improvement of the PREMM5 model
Since location of CRC was the only significant difference 
between PMS2 mutation carriers and non-mutation carri-
ers, we incorporated this variable in the PREMM5 model, 
aiming to improve the prediction model. For PMS2 muta-
tion carriers, the extended PREMM5 model had consider-
ably better predictions than the original  PREMM55 model 
(AUC 0.77 [95% CI 0.63–0.90] vs. 0.51 [95% CI 0.35–0.66]) 
(Fig. 2). At a 5% cut-off, the new PREMM5 model identified 
5/6 PMS2 mutation carriers that would have been missed by 
PREMM5 and 3/4 PMS2 mutation carriers that would have 
been missed by MMRpredict at the same cut-off.
Adding tumour location also improved the performance 
of PREMM5 for identifying MLH1 (AUC 0.92 [95% CI 
0.88–0.97] vs. 0.80 [95% CI 0.71–0.89]) and MSH6 (AUC 
0.75 [95% CI 0.65–0.84] vs. 0.69 [95% CI 0.58–0.80]) 
mutation carriers (Fig.  2). However, performance for 
MSH2 mutation carriers slightly decreased (AUC 0.80 [95% 
CI 0.69–0.91] vs. 0.83 [95% CI 0.73–0.94]). Overall, the 
adjusted PREMM5 model performed better than the original 
PREMM5 model (AUC 0.81 [95% CI 0.76–0.86] vs. 0.72 
[95% CI 0.66–0.79]) and MMRpredict (AUC 0.81 vs. 0.73 
[95% CI 0.66–0.79]). The adjusted prediction model can be 
found as supplemental material.
At a 5% cut-off, sensitivity of the extended PREMM5 
model was higher than the sensitivity of the original 
PREMM5 model (92 vs. 78%) with similar specificity 
(45 vs. 46%). Sensitivity and specificity of the extended 
PREMM5 model at a 5% cut off were both higher than those 
of the revised Bethesda guidelines (sensitivity 92 vs. 90% 
and specificity 45 vs. 24%).
Validation of the extended PREMM5 model
In our validation cohort, 60% of the patients were male and 
median age was 55 years (IQR 45–63 years). The cohort 
included 31 MLH1, 26 MSH2, 28 MSH6 and 73 PMS2 muta-
tion carriers. Similar to the results in the initial cohort, the 
extended PREMM5 model had better predictions than the 
original PREMM5 model for PMS2 mutation carriers (AUC 
0.90 [95% CI 0.86–0.94] vs. 0.82 [95% CI 0.76–0.87]) and 
Table 2  Index characteristics 
and family history for PMS2 
mutation carriers compared 
with non-mutation carriers
Mutation negative, % (n) PMS2 mutation posi-
tive, % (n)
P value
n 651 12
Revised Bethesda guidelines 76% (494) 83% (10) 0.74
Index characteristics
 Male gender 47% (305) 50% (6) 0.83
  CRC
   Age CRC (median, IQR) 53 years [45–62] 46 years [40–61] 0.21
   Proximal CRC 28% (185) 83% (10) < 0.001
   ≥ 2 CRCs 10% (66) 8% (1) 1.0
  Endometrial cancer 3% (11) 0% (0) 1.0
   Age EC (median, IQR) 55 years [50–75]
  Multiple LS cancers 4% (27) 0% (0) 1.0
First degree relatives
 CRC 55% (358) 42% (5) 0.36
  ≥ 2 FDRs with CRC 16% (107) 8% (1) 0.70
  Age CRC (median, IQR) 64 years [55–71] 62 years [45–90] 0.68
 Endometrial cancer 5% (35) 17% (2) 0.14
  ≥ 2 FDRs with EC 0.6% (4) 8% (1) 0.88
  Age EC (median, IQR) 55 years [50–64] 37 years [–] 0.24
 Other LS cancers 22% (142) 8% (1) 0.48
Second degree relatives
 CRC 33% (212) 17% (2) 0.35
  ≥ 2 SDRs with CRC 12% (81) 8% (1) 1.0
  Age CRC (median, IQR) 62 years [50–74] 39 years [39–] 0.12
 Endometrial cancer 3% (22) 8% (1) 0.35
  ≥ 2 SDRs with EC 0.3% (2) 8% (1) 0.05
  Age EC (median, IQR) 70 years [50–76] 49 years [–] 0.67
 Other LS cancers 16% (104) 17% (2) 1.0
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overall (AUC 0.92 [95% CI 0.89–0.95] vs. 0.87 [95% CI 
0.84–0.91]). Performance for MLH1, MSH2 and MSH6 
mutation carriers was also slightly better for the extended 
PREMM5 model than for the original PREMM5 model 
(AUC 0.97 [95% CI 0.94–1.00] vs. 0.95 [95% CI 0.91–0.99] 
for MLH1,0.97 [95% CI 0.93–1.00] vs. 0.96 [95% CI 
Fig. 2  Performance of PREMM5 and the extended PREMM5 model in a clinical setting for all mutation carriers and for individual MMR muta-
tions
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0.92–0.99] for MSH2 and 0.86 [95% CI 0.97–0.93] vs. 0.85 
[95% CI 0.77–0.93] for MSH6 mutation carriers).
Discussion
The results of our study indicate that while the models 
MMRpredict and PREMM5 can adequately predict whether 
an individual is likely to have Lynch syndrome, they fail 
to identify PMS2 mutation carriers. The performance of 
the PREMM5 model improved considerably by adding the 
location of CRC to the model. In our clinical cohort of 734 
CRC patients as well as in a validation cohort of 376 CRC 
patients, this extended PREMM5 model not only identified 
PMS2 mutation carriers more accurately, its overall perfor-
mance was also better than the original PREMM5 model and 
the MMRpredict model.
Our results are in line with those of previous studies, 
where the  PREMM1,2,6 model had a slightly better over-
all performance than MMRpredict [22, 32, 33]. The first 
PREMM model,  PREMM1,2 also performed better than 
MMRpredict in several studies [23, 24], but had similar 
[25, 26] or less accurate [21] predictions in other studies. A 
recent meta-analysis also found pooled AUCs to be higher 
for the PREMM model than for MMRpredict (AUC 0.84 
vs. 0.81) [27].
Although PREMM5 had better overall predictions, 
MMRpredict had a better performance for PMS2 mutation 
carriers specifically. An explanation for this could be that the 
location of CRC is incorporated in the MMRpredict model 
but not in the  PREMM5 model. Proximal location of CRC 
is a known predictor for Lynch syndrome and in our cohort 
was the only significant difference between PMS2 mutation 
carriers and non-mutation carriers. After adding this new 
variable to the existing  PREMM55 model, this new model 
performed better than MMRpredict for PMS2 mutation car-
riers. The extended  PREMM55 model also performed better 
than the original model for MLH1, MSH2 and MSH6 muta-
tion carriers and had a better overall performance.
In our validation cohort, all AUCs were much higher than 
in our original cohort, including those for PMS2 mutation 
carriers. Selection of patients for analysis of MSI and IHC 
may have been less stringent at the Erasmus Medical Center 
Rotterdam than at the Leiden University Medical Center. 
Therefore, mutation carriers in our validation cohort, who 
were all from Leiden University Medical Center, may have 
had a family history more suspect for Lynch syndrome than 
family history of the patients in our original cohort. This 
could explain the higher AUCs in the validation cohort. 
However, in both cohorts we showed that the extended 
PREMM5 had better performance.
Prediction models for Lynch syndrome are not yet reg-
ularly used in current clinical practice. However, the US 
Multi-Society Task Force on Colorectal Cancer recom-
mends genetic evaluation if an individual’s risk of carrying 
an MMR gene mutation is ≥ 5% according to one of the 
prediction models MMRpro, MMRpredict or PREMM [34]. 
The American guideline recommends that all CRC patients 
undergo routine screening for LS by analysis of MSI and 
IHC [34], while current European guidelines recommend 
such routine screening in at least all CRC patients up to 
70 years of age [35]. A recent study demonstrated that rou-
tine screening for LS without an age cut-off is not cost-effec-
tive [36]. A strategy using prediction models might lower 
the cost of screening for LS. In fact, two cost-effectiveness 
analyses found that strategies including prediction models 
were more cost-effective than those involving direct tumour 
testing of all CRC patients, if these prediction models were 
perfectly implemented [36, 37]. Additionally, prediction 
models could also be used in cases where no tumour tissue 
is available or where tumour tissue analysis failed, to assess 
whether an individual should be analysed for a germline 
MMR mutation.
The US Multi-Society Task Force on Colorectal Cancer 
recommends the use of either PREMM, MMRpredict or 
MMRpro to assess the probability of an individual carrying 
an MMR mutation [34]. Since we did not include the MMR-
pro model in our analysis, we do not know how MMRpro 
would have performed in our cohort. However, MMRpro is 
less useful in clinical practice since extensive family data 
is needed as input for the model. Collection of this kind of 
data is very time consuming and therefore not suitable in 
clinical practice. PREMM5 and MMRpredict are web-based 
models that are easily accessible and therefore much easier 
to use. Also, multiple studies—including the recent meta-
analysis—have shown MMRpro to have similar accuracy to 
 PREMM1,2,6 [21–27, 32].
Both PREMM5 and MMRpredict were far more accurate 
for MLH1 and MSH2 mutation carriers than for LS patients 
carrying a mutation in MSH6 or PMS2. This finding is in 
line with a previous study that showed that carriers of muta-
tions in MSH6 or PMS2 had lower risk scores than carriers 
of a mutation in MLH1 or MSH2 [21]. In our study, discrimi-
nation between non-mutation carriers and PMS2 mutation 
carriers was the least accurate, in line with its more limited 
penetrance.
Around 15% of all Lynch syndrome cases are estimated 
to be caused by PMS2 mutations [38]. In our cohort, 14% 
(12/83) of the Lynch syndrome patients were PMS2 muta-
tion carriers. To our knowledge, our study is the first to vali-
date LS prediction models for PMS2 mutation carriers spe-
cifically since the development of the PREMM5 model. At a 
5% cut-off, our extended PREMM5 model was able to detect 
5/6 PMS2 mutation carriers who would have been missed by 
the original PREMM5 model at the same cut-off. Identifica-
tion of Lynch syndrome carriers is highly important, since 
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this allows not only them, but also their family members 
carrying the same mutation, to undergo intensive surveil-
lance in order to prevent the development of cancer. Our new 
model would also identify more Lynch syndrome patients 
overall than the original PREMM5 model.
The performance of prediction models can differ between 
high-risk settings and population-based cohorts. Further 
validation studies should indicate whether our results can 
be generalized to settings with patients at low to median 
risk of having Lynch syndrome. Since patients in our study 
cohort were all referred for genetic counselling, family his-
tories were obtained in detail and in many cases also verified 
by medical documents. In other settings where patients are 
at lower risk of having Lynch syndrome, family history is 
not verified and might be less reliable. Therefore, predic-
tion models should also be validated in population-based 
cohorts. However, in a meta-analysis, prediction models 
performed better in population-based cohorts than in clinic-
based cohorts [27].
It is not known whether the current prediction models 
for Lynch syndrome are useful in non-Western populations. 
In a recent study among Korean patients,  PREMM1,2,6 was 
more accurate than MMRpro and MMRpredict, but still 
only reached an AUC of 0.71 [32]. There was no associa-
tion between tumour location and mutation status, so our 
extended PREMM5 model might not improve predictions 
in populations of non-Western ethnicity. However, germline 
analysis for PMS2 was not performed in the Korean study, so 
there might have been more mutation carriers in their cohort. 
Another non-Western population has been studied by Khan 
et al., who analysed the performance of prediction models in 
15 African American patients [22]. In these patients, MMR-
predict and  PREMM1,2,6 both had a high AUC of 0.89.
A main strength of our study was the large cohort, which 
consisted of more than 700 index patient including 83 Lynch 
syndrome patients. Also, our cohort included patients with 
MSH6 and PMS2 mutations. Since 12 patients were identi-
fied as a PMS2 mutation carrier, we were able to evaluate 
the prediction models for each MMR mutation specifically, 
admittedly with considerable uncertainty [39]. Furthermore, 
we validated the extended PREMM5 model in a separate 
cohort of 376 patients including 73 PMS2 mutation carriers.
A limitation of our study was that germline mutation 
analysis was not done for all index patients. Patients who 
had microsatellite stable tumours with normal IHC were 
assumed to be non-mutation carriers. However, some of 
these patients might still have an MMR mutation. Also, 
the sample size per gene was still relatively small and it 
is unclear whether our results from a high-risk population 
apply to a population-based setting.
In conclusion, we have shown that although MMRpredict 
and PREMM5 can accurately predict an individual’s risk of 
carrying a causative MMR mutation, neither model is able to 
identify patients with PMS2 mutations. Adding the location 
of CRC to the PREMM5 model improves the performance of 
the model for PMS2 mutation carriers as well as its overall 
performance. These findings should be validated in large 
cohorts from population-based settings.
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